Background and objective: The impact, treatment patterns and control of mild asthma are poorly understood for Chinese patients. This study describes the characteristics, therapeutic interventions and burden of mild asthma on patients residing in major cities of China. Methods: The Respiratory Disease Specific Program 2015, a cross-sectional survey, was conducted with Chinese physicians and their patients. The survey assessed clinical characteristics, asthma symptoms, exacerbations, rescue inhaler usage, treatment adherence, asthma control, work and activity impairments and healthcare utilization for patients prescribed Global Initiative for Asthma (GINA) Step 1 or 2 treatment defined mild asthma. Results: From a total sample of 988 patients, 229 patients met the criteria for mild asthma, with 25.3% classified as Step 1 and 74.7% as Step 2. Overall, 12.6% of patients were considered of high adherence to prescribed treatment. Physicians reported that 75% of patients overall were well controlled, although wellcontrolled asthma as defined by GINA was achieved in only 14.2% of patients. 26.5% of patients indicated daily use of as-needed rescue medication in the last 4 weeks. 17.8% of patients experienced ≥1 exacerbations in the last 12 months and impaired work productivity was 27.2% overall. Conclusion: Less than 15% of patients were well controlled according to GINA criteria despite physicians reporting the majority of patients were well controlled. Over one-fourth of patients relied on daily rescue inhaler medication, while exacerbation frequency and work and activity impairment were higher than might reasonably be expected in a mild asthmatic population.
INTRODUCTION
Asthma is a common, chronic respiratory disease estimated to affect 1.0-18.0% of the population depending on the country. 1, 2 The 2002 prevalence estimates of 3.0-6.0% for Asia-Pacific nations are lower compared with Western countries, although prevalence in Asia appears to be on the rise. [3] [4] [5] [6] This increase has been attributed to environmental exposures, 2, 7 with children and the elderly at highest risk. 8 Thirty million people in China are affected by asthma. 9 A household survey of more than 180 000 individuals 14 years or older residing in eight provinces of China revealed an overall asthma prevalence of 1.2%, [10] [11] [12] while other studies report a prevalence of 1.1% across all age groups. Prevalence is higher in urban areas at 1.4% versus 0.9% for rural locations. 13 Crucially and consistent with trends in other AsiaPacific countries, asthma prevalence in China appears to be increasing. 13 Treatment goals include optimal symptom control, maintenance of normal activity levels and reductions in exacerbations and fixed airflow limitations, with minimal side effects. 1 Pharmacological treatment options are guided by severity. 1 Mild asthma is asthma that is well controlled with Step 1 or Step 2 treatment including as-needed reliever medication monotherapy (Step 1) or a low-intensity controller treatment, such as lowdose inhaled corticosteroids (ICS), leukotriene receptor antagonists (LTRA) or theophylline (Step 2). 1 Among 59 935 respondents to the China National Health and Wellness Surveys conducted between 2010 and 2013, 1.99% reported a diagnosis of asthma, with 77.0% considered to have mild asthma based on GINA guidelines.
14 A cross-sectional survey of 13 645 individuals residing in Jinan, China, revealed that poor asthma 
SUMMARY AT A GLANCE
This observational study of Chinese patients with mild asthma reveals that physicians considered 75% to be well or completely controlled, although only 14.2% were well controlled according to the Global Initiative for Asthma criteria. Treatment adherence was low, and many patients experienced nocturnal symptoms, exacerbations and work and activity impairments.
control was attributed to suboptimal adherence to the GINA treatment guidelines and underutilization of ICS. 15 Treatment patterns, adherence and control among patients with mild asthma in China is not well understood or studied, although some evidence suggests that the impact is greater than expected due to inadequate treatment. Among 950 patients in Italy with mild asthma, 35.3% were considered poorly controlled despite ICS therapy. 16 This study described patient characteristics, treatment patterns and disease burden in individuals with mild asthma residing in urban areas of China.
METHODS

Study design
This was an analysis of the Respiratory Disease Specific Program (DSP), a large, multinational, cross-sectional survey that collects real-world data from physicians and patients; a complete description of the DSP methods was previously published. 17 Data were collected during the first quarter of 2015 from nine major cities in China, including Beijing, Chengdu, Guangzhou, Jinan, Nanjing, Shanghai, Shenyang, Wuhan and Xi'an. Local fieldwork partners collected the physician-and patient-completed forms, with all patient-identifying information removed before submission of the completed forms for analysis. Unique identifiers were assigned to physicians and patients to permit a linked analysis of patient-completed surveys with the corresponding physician surveys.
The Respiratory DSP was conducted as a market research survey and adhered to the research guidelines of the ICC/ESOMAR (International Chamber of Commerce / European Society for Opinion and Marketing Research) Code on Market and Social Research and the Chinese Market Research Association. Ethics approval was not sought because this survey was conducted as non-interventional market research. All adult participants provided written informed consent to participate in this study, while parents, guardians or next of kin provided written informed consent for minors to participate.
Subjects
Physicians were eligible if they qualified as Chief Doctor, Vice Chief Doctor or Doctor in Charge; were personally responsible for the treatment of patients with asthma; and cared for at least 15 asthma patients per month. Eligible patients were 12 years or older with a physician-confirmed diagnosis of asthma, excluding those with a concomitant diagnosis of chronic obstructive pulmonary disease.
Assessments
Physicians completed a patient form for their next four consecutive asthma patients and the next consulting patient currently prescribed a GINA Step 1 (as-needed reliever medication monotherapy) or Step 2 (single controller treatment of low-dose ICS, LTRA or theophylline) treatment. 1 Physicians and patients provided information on demographic and clinical characteristics, most recent forced expiratory volume in 1 s (FEV 1 ) percent predicted, smoking history, co-morbid health conditions, asthma control and severity and the frequency and timing of asthma symptoms and exacerbations.
Physicians also reported current prescribed treatments, use of traditional Chinese medicine (TCM) and their perception of patients' asthma control recorded on a 5-point scale ranging from not at all controlled to completely controlled. Patients with mild asthma were identified retrospectively according to the prescribed treatment regimen at the time of the survey based on physicians' record of current drug(s) and dosage. 1 The Morisky Medication Adherence scale (MMAS-8) 18 assessed treatment adherence, with low adherence defined by scores <6, moderate adherence as scores of 6 to <8 and high adherence as a score of 8. Patientreported asthma control was measured with the Asthma Control Test (ACT). 19 The Work Productivity and Activity Impairment (WPAI) questionnaire 20 yielded four scores for work missed (absenteeism), impaired time at work (presenteeism), overall work impairment (combination of absenteeism and presenteeism) and total activity impairment.
Statistical analysis
Descriptive statistics were calculated for all variables, with patients stratified as total mild, GINA Step 1 and GINA Step 2. Control classification according to GINA was derived based on patients' assessment of the frequency of daytime symptoms (more than twice a week), any nocturnal awakening, rescue inhaler usage (more than twice a week) and any activity limitation in the past 4 weeks. Well-controlled asthma was when none of these criteria were met, partly controlled where one or two of these were present and uncontrolled where three or all four were present. 1 We included the maximum sample available for each variable when calculating descriptive statistics. This differed between variables due to the source of information. All analyses were performed by Adelphi Real World (Bollington, UK) using Stata 13.1.
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RESULTS
Eligible physicians completed 988 patient record forms. Of these, 229 met the inclusion criteria for mild asthma, with 25.3% classified as Step 1 and 74.7% as
Step 2 (Fig. S1 , Supplementary Information).
Demographic and clinical characteristics of patients
The highest percentage of patients was from Shanghai (21.5%). Overall, 47.2% of patients were males and mean age was 42.9 years. Almost half reported at least a university education. Current tobacco use was reported for 10.6% of patients, and basic employee medical insurance was covered by 73.7% of patients. The most common co-morbidities were allergic rhinitis (25.3%) and hypertension (10.5%). Demographic and clinical characteristics are presented in Table 1 . Overall (n = 229)
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Step 2 (n = 171) (Table 2 ). Only 13.8% of patients were classified as high adherers (Table 2) .
Asthma control
Physicians' evaluations of asthma control indicated that 75.0% of patients overall were considered 'well' or 'completely' controlled, including 84.2% GINA Step 1 and 71.9% Step 2 patients (Fig. 1A) . According to GINA guidelines, well-controlled asthma was achieved in 14.2% of patients and 73.5% were classified as partly controlled (Fig. 1B) . The mean ACT score was 21.2 for low adherence patients, 22.1 for medium adherence and 21.8 for the high adherence group. Among high and medium adherence Step 2 patients, 73.3% and 76.9%, respectively, were partly controlled while 20.0% of high adherence patients and 15.4% of medium adherers were well controlled.
Asthma symptoms
Shortness of breath (SOB) due to exercise or exertion was the most frequently reported symptom by both physicians and patients at 44.9% and 49.2%, respectively. The frequency of patient-reported SOB upon exertion was higher among GINA Step 1 patients (60.0%) compared with those at Step 2 (45.6%), which was consistent with the physician-reported frequency of SOB upon exertion ( Table 3) .
The most troublesome symptoms occurred primarily at night or only during the night for 32.4% and 39.0% of patients as reported by physicians ( Fig. 2A) and patients (Fig. 2B) , respectively. Among GINA Step 1 patients, 29.5% reported their symptoms as most troublesome at night-time compared with 12.3% by physicians. Approximately 40% of GINA Step 2 patients reported night-time symptoms as the most bothersome as reported by both physicians and patients. Daily use of as-needed rescue medication in the last 4 weeks was reported by 26.5% of patients.
Lung function
The most recent mean pre-bronchodilator FEV 1 was 73.7% predicted. However, this assessment was missing for 61.1% of patients suggesting lung function testing was not routinely performed.
Asthma exacerbations
Overall, 17.8% of patients experienced one or more exacerbations in the last 12 months including 10.5% and 20.2% of GINA Step 1 and 2 patients, respectively ( Table 3) .
Impact of asthma
Overall work impairment was reported as 27.2%, including 34.0% of Step 1 and 25.5% of Step 2 patients. The overall absenteeism was 5.8% in the past 7 days. Presenteeism was reported as 24.6% overall, 31.7% for GINA Step 1 patients and 22.7% of GINA Step 2 patients. Overall activity impairment was 34.4% (Fig. 3) .
The overall mean number of physician visits was 4.7 (AE3.6), with a higher mean number of visits for GINA Step 1 patients. Overall, 14% had ≥1 visit to the emergency department (ED) for the treatment of exacerbations in the last 12 months (Table 3) .
DISCUSSION
Patients with mild asthma defined by GINA Step 1 or 2 treatment should be relatively well or completely controlled with few symptoms and no risk for exacerbations. This study of Chinese patients with mild asthma revealed that the majority of physicians perceived their patients as well or completely controlled. However, only 14.2% of all patients were classified as well controlled according to GINA criteria, a finding confirmed by other researchers. 22 Of note, there was a high frequency of nocturnal symptoms, exacerbations and rescue inhaler usage. Table 3 Physician-and patient-reported symptoms, FEV 1 , asthma control, physician visits and exacerbation history by GINA Step Overall (n = 229)
GINA Step
Step 2 (n = 171) Other studies confirm that the majority of asthma patients in Asia-Pacific countries are not well controlled. 3, 23 The Asthma Insight and Management survey revealed that 69.0% of patients in China self-reported their asthma as completely controlled or well controlled in the preceding 4 weeks. 23, 24 However, 42.0% were uncontrolled, 56.0% partly controlled and only 2.0% were well controlled based on the GINA criteria. 23, 24 A cross-sectional survey of Chinese residents 14 years or older residing in eight cities found that 15.6% were fully controlled and 49.5% were well controlled based on the ACT, although 22.6% were hospitalized and 27.0% required emergency care for exacerbations in the past year.
11 Among more than 3000 adults attending outpatient respiratory clinics in 10 geographically dispersed cities in China, only 28.7% met the GINA criteria for well-controlled asthma. 25 Our study identified work and activity impairments of 27.2% and 34.4% in the past 7 days, respectively. A slightly higher proportion of GINA Step 1 patients had greater impairments at work, overall activity level and presenteeism compared with Step 2 patients. Such impairments are likely associated with significant indirect economic costs, restrictions in daily activities and diminished quality of life.
Together, these results indicate that asthma patients residing in Asia-Pacific countries, including China, overestimate their level of disease control and experience significant impairments, which may have a substantial impact on health, healthcare utilization and Table 3 Continued Overall (n = 229)
Step 2 (n = 171) Overall work impairment Total activity impairment Figure 3 Work productivity and activity impairment: absenteeism, presenteeism, overall work impairment and total activity impairment by GINA Step ( , total mild asthma (n = 105); , GINA Step 1 (n = 21); , GINA Step 2 (n = 84)). GINA, Global Initiative for Asthma. quality of life. 23, 26 Patients with mild asthma may perceive their disease as controlled and not serious despite the experience of symptoms and exacerbations. 23, [27] [28] [29] [30] Patients may accept their symptoms and be less likely to adhere to preventive therapy. They also may not understand that therapy will control current symptoms and reduce their risk of asthma worsening. [29] [30] [31] More than half of the patients in our sample had low or medium adherence to treatment, which may reflect a lack of concern about asthma or a failure to understand the importance of control for optimal long-term outcomes. Patients may be unaware of the distinction between poor and good asthma control and may not understand how their symptoms could be more effectively controlled with medical therapy.
Patients may also lack confidence in treatment efficacy, which has been shown in other research. 12 Interviews with Chinese adult asthmatic patients revealed that 49.1% believed that there was no effective treatment for asthma. 12 Concerns about the safety of ICS and uncertainty about the effectiveness of asthma medications were associated with low adherence in asthma patients from six Asian countries. 32 The main reason for non-adherence cited by patients and physicians in China and six other Asia-Pacific countries was the perception that daily inhaler use was not necessary. 22 Nocturnal symptoms affected more than 90.0% of patients in our study and were considered most bothersome by one-third of patients overall, a higher rate than observed in the USA and EU. 33 Treatment for Step 2 patients in China also was more varied than in the EU or the USA, 14 with ICS less likely to be prescribed. A substantial percentage of patients in our study were prescribed antitussive or mucolytic medications to supplement asthma-specific medications. These prescribing patterns may represent acute therapy for the prevalent symptoms of cough instead of regular usage of maintenance medications.
Overall, almost 20.0% of patients experienced one or more exacerbations in the previous 12 months, including 10.5% of Step 1 patients, suggesting that these patients may benefit from a Step increase in treatment. 1 These results are consistent with those of an earlier analysis of data collected in 2000 from patients in France, Germany, Italy, Spain, the UK and the USA, 34 and highlight a persistent unmet need for a significant proportion of mild asthmatic patients. Step 2 patients were also possible candidates for a Step increase in treatment, although adherence was likely to affect control.
Asthma management strategies should focus on prevention rather than emergent relief of exacerbations and symptoms. 22 Improved adherence may be achieved through asthma management plans, the review of treatments and patient education to reinforce the importance of adherence and correct inhaler technique. 26 This study has several limitations. Patient exclusion criteria were largely related to missing data and limit the full generalizability of our findings. The diagnosis of asthma was confirmed by physicians, which depended on diagnostic skills rather than a predetermined set of disease parameters enforced by a research protocol. However, physician diagnosis is an accepted method for the identification of target samples in realworld research.
The quality of our data depended on accurate reporting by physicians and patients. Minimal exclusion criteria were imposed on physicians, although physician inclusion was likely influenced by their willingness to participate in this study. Our survey focused on patients attending large hospitals in major cities compared with those residing in rural communities, limiting the generalizability of our results to patients residing in urban China. Physicians could refer to medical records to limit errors when reporting actual treatments, events and comorbidities. The majority of questions related to current or recent symptoms and events, thereby limiting recall bias. A 12-month recall period was used for exacerbations. Given the severity of such events, it is reasonable to expect higher recall accuracy.
In conclusion, despite the majority of mild asthma patients being classified as well or completely controlled by physicians, a high proportion were not well controlled according to GINA guidelines. While external factors such as the environment, lifestyle and treatment adherence influence asthma control, this study shows that 80-90% of mild asthmatic patients received non-steroidal and short-acting only medications and may benefit from treatment intensification.
